In-Office Procedures
At District Endocrine, we perform specialized procedures across our Woodbridge, Burke Fairfax, and Manassas locations — no separate hospital or outside facility visit required.
Thyroid Ultrasound
We perform in-office thyroid ultrasounds to evaluate thyroid nodules, goiter, and thyroid gland structure. Our physicians assess nodule size, characteristics, and risk features in real time — without a separate radiology appointment.
When Is It Ordered?
- Evaluation of a palpable thyroid nodule or neck lump
- Monitoring of known thyroid nodules over time
- Assessment of goiter or diffuse thyroid enlargement
- Follow-up after thyroid cancer treatment
- Evaluation in the setting of abnormal thyroid function tests
Thyroid Fine Needle Aspiration (FNA) Biopsy
When a thyroid nodule requires tissue sampling, we perform FNA biopsy in-office under ultrasound guidance — a minimally invasive procedure collecting cells for pathology review without surgery.
What to Expect
- Performed under real-time ultrasound guidance for precision
- Approximately 15–20 minutes in the office
- Local anesthetic used — most patients experience minimal discomfort
- Pathology results typically available within 1–2 weeks
- No hospital visit, general anesthesia, or surgical incision
CGM Initiation & Training
We initiate and train patients on CGMs including Dexcom G7 and FreeStyle Libre 3 directly in our office — providing real-time glucose readings and trends that improve diabetes management for Type 1 and Type 2 diabetes.
- Device selection guidance based on insurance and clinical needs
- Hands-on sensor placement and smartphone app setup
- Integration with insulin pumps and automated insulin delivery systems
- Remote CGM data review between office visits
Prolia (Denosumab) Injections
Prolia (denosumab) is an FDA-approved injection for osteoporosis given every 6 months that inhibits bone resorption to reduce fracture risk. We administer Prolia in-office and coordinate scheduling to maintain the correct dosing interval.
- Given every 6 months — timing is critical to prevent rebound bone loss
- Calcium and vitamin D checked before each dose
- Contraindicated in hypocalcemia
- Transition therapy required when discontinuing Prolia
Evenity (Romosozumab) Injections
Evenity (romosozumab) is an FDA-approved injectable treatment for severe osteoporosis in postmenopausal women at high risk of fracture. Unlike Prolia, Evenity has a dual mechanism — it simultaneously builds new bone and reduces bone breakdown, making it one of the most powerful bone-building agents available. It is administered as two subcutaneous injections once monthly for 12 months, after which transition to an antiresorptive therapy is required.
- Two subcutaneous injections given once monthly for 12 months
- Dual action — stimulates bone formation and inhibits bone resorption
- Calcium and vitamin D levels checked before initiating therapy
- Contraindicated in patients with recent (within the past year) heart attack or stroke
- Carries a boxed warning for cardiovascular risk — full cardiac history reviewed before prescribing
- Transition to Prolia or a bisphosphonate required after completing the 12-month course
Testosterone Injection Training
For patients prescribed injectable testosterone, we provide in-office training for safe self-administration at home — covering technique, site rotation, and safety practices for your specific formulation.
- Injection technique — intramuscular or subcutaneous depending on formulation
- Correct needle and syringe selection
- Injection site selection and rotation to prevent tissue buildup
- Safe sharps disposal practices
- Signs to watch for — infection, dose errors, or adverse reactions